Portman Square Capital LLP Neurocrine Biosciences Inc Transaction History
Portman Square Capital LLP
- $2.72 Billion
- Q2 2024
A detailed history of Portman Square Capital LLP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Portman Square Capital LLP holds 10,457 shares of NBIX stock, worth $1.27 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
10,457
Previous 95,600
89.06%
Holding current value
$1.27 Million
Previous $13.2 Million
89.09%
% of portfolio
0.05%
Previous 0.4%
Shares
2 transactions
Others Institutions Holding NBIX
# of Institutions
641Shares Held
95.3MCall Options Held
661KPut Options Held
227K-
Black Rock Inc. New York, NY14.2MShares$1.72 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.22 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$559 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$299 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$286 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.6B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...